Abstract
Introduction

1
The well-documented tumor suppressor p53, referred as "the guardian of the genome", is 2 activated upon exposure to a myriad of cellular stresses. While loss of wild type p53 causes fatal 3 damages to cells, it is not surprising that the TP53 gene is mutated in more than 50% human deactivates this protein by either abrogating its transcriptional activity, or inducing its nuclear 8 export and ubiquitination [2] [3] [4] [5] . A plethora of cellular stress could stabilize p53 by blocking the 9 MDM2-p53 feedback loop 6 . For example, p19 ARF inhibits MDM2-mediated p53 ubiquitination 10 and proteolysis by associating with MDM2 7 .
11
Another pathway is so-called the ribosomal proteins (RPs)-MDM2-p53 pathway 8, 9 .
12
Accumulating evidence has continuingly verified this pathway as an emerging mechanism for 13 boosting p53 activation in response to ribosomal stress or nucleolar stress over the past decade suggesting its role in rRNA synthesis.
2
In screening uL18-associated protein complexes using co-immunoprecipitation followed by mass 3 spectrometry, we identified SPIN1 as one of the potential uL18 binding proteins. We confirmed 4 the specific interaction of SPIN1 with uL18, but not with uL5 or uL14, and also found out that 5 by binding to uL18, SPIN1 prevents the inhibition of MDM2 by uL18 and promotes MDM2-6 mediated p53 ubiquitination and degradation. Also, SPIN1 knockdown induced ribosomal stress 7 by facilitating the release of ribosome-free uL18 or uL5, accompanying p53 activation. 
RESULTS
15
SPIN1 interacts with uL18.
16
Our and others' studies previously demonstrated that uL18 can stabilize p53 by binding to
17
MDM2 and inhibiting its E3 ligase activity toward p53 19, 35 . In order to identify potential 18 upstream regulators that may modulate the uL18-MDM2-p53 circuit, we performed co-
19
immunoprecipitation (co-IP) using HEK293 cells that stably expressed Flag-uL18 with the anti-
20
Flag antibody, and the co-immunoprecipitated proteins were cut out for mass spectrometric (MS) 21 analysis (Fig. 1A) . The MS results not only revealed several previously described p53 regulatory 22 proteins, such as MYBBP1A, PRMT5 and SRSF1, as uL18 binding proteins (Table S1 ), but also 23 identified SPIN1 as a novel uL18-binding protein candidate that was previously shown to play a 24 role in tumorigenesis and rDNA transcription 30,34 .
25
Next, we confirmed the interaction between SPIN1 and uL18 by performing a series of 26 reciprocal co-IP assays. As expected, ectopic SPIN1 was specifically pulled down by ectopic 27 uL18 and vice versa in HCT116 p53-/-cells ( Fig. 1B and 1C) . Their interaction was also verified in
28
HEK293 cells ( Supplementary Fig. S1 ). Also, we validated the interaction between endogenous
29
SPIN1 and uL18 in HEK293 cells using anti-SPIN1 antibody (Fig. 1D) and PUMA, were also increased in response to SPIN1 knockdown ( Fig. 2A and 2B ). Moreover,
15
the effects of SPIN1 siRNA on p53 activity were dose-dependent ( Supplementary Fig. S2 ).
16
Conversely, overexpression of SPIN1 in HCT116 p53+/+ decreased the protein levels of p53 and its 17 targets, such as p21 and PUMA, and the mRNA levels of these target genes, without affecting 18 p53 mRNA level ( Fig. 2C and 2D ).
19
We next generated both HCT116 p53+/+ and HCT116 p53-/-cell lines that express scramble shRNA 20 or SPIN1 shRNA to evaluate biological outcomes of SPIN1 knockdown. As illustrated in Fig. 2E function of uL18, since SPIN1 could bind to uL18 (Figure 1 ), knockdown of SPIN1 led to p53 29 activation (Fig. 2) , and SPIN1 inhibited MDM2-mediated p53 ubiquitination (Fig. 3) forms of ribosomal proteins in SPIN1 ablation-induced p53 activation, we knocked down uL18 2 or uL5 using siRNA with or without SPIN1 depletion in U2OS cells. Strikingly, the reduction of 3 either uL18 or uL5 abrogated SPIN1 knockdown-induced p53 levels, as well as its target p21, as 4 compared to scramble siRNA-transfected cells ( Fig. 5D and 5E ). Collectively, these data indicate 5 that knockdown of SPIN1 could also lead to ribosomal stress, releasing ribosome-free uL18 and 6 uL5, which are required for p53 activation induced by SPIN1 depletion. Mapping of uL18-and SPIN1-binding domains.
9
To understand the physical interaction between SPIN1 and uL18 in more details, we generated 10 recombinant GST-SPIN1 and His-uL18 proteins covering full-length or different domains. Our
11
GST-pull down assay showed direct interactions between these two full-length proteins ( SPIN1 depletion impedes xenograft tumor growth.
28
To translate the above-described cellular functions of SPIN1 into more biological significance, through interplay with uL18 (Fig. 6E) . Our studies as presented here provide the first line of 5 evidence for that SPIN1 acts as an upstream regulator of uL18's accessibility to MDM2 for p53 6 activation.
7
Using IP-MS analysis, we identified SPIN1 as a new uL18-associated protein (Fig. 1A) . Our 8 biochemical and cellular experiments using co-IP and GST pull down assays further validated 9 the direct association of SPIN1 with uL18 ( Fig. 1B-1D ; Fig. 6A-6D ). Moreover, we found that 10 SPIN1 and uL18 co-localized in the nucleolus by immunofluorescence assay ( Fig. 4D and S3B ).
11
Remarkably, SPIN1 specifically binds to uL18, but not uL5 and uL14, as no binding was 12 detected between ectopic SPIN1 and uL5 or uL14 by co-IP (Fig. 1E) . Interestingly, SPIN1 does 13 not appear to bind to MDM2, as it was not co-immunoprecipitated with MDM2 either (Fig. 4B ).
14 Although our previous reports described a complex of uL18/uL5/uL14 presented here showed that SPIN1 depletion by its specific shRNA leads to the augment of the 25 p53-dependent cancer cell growth arrest and apoptosis. This is at least partly because SPIN1 can 26 promote MDM2-dependent ubiquitination and degradation of p53 (Fig. 3) , which is highly likely 27 attributable to its capability to prevent uL18 from binding to MDM2 through retaining uL18 in 28 the nucleolus (Fig. 4E ).
29
Also, knockdown of SPIN1 led to the increase of ribosome-free uL18 and uL5 levels, of the 30 uL18/uL5-MDM2 complex, and of p53 level and activity ( Fig. 5A and 5B). Actinomycin D treatment (Fig. 5C ), whereas knockdown of uL18 or of uL5 impaired the 4 activation of p53 by SPIN1 knockdown (Fig. 5D and 5E as a negative regulator of p53. Therefore, our present findings unveil a novel mechanism for 10 suppression of the uL18-MDM2-p53 pathway by SPIN1, whose depletion consequently leads to 11 p53-dependent cell growth inhibition and apoptosis.
12
Consistent with its oncogenic activity, SPIN1 is often amplified in a panel of cancer types with predominantly in wild type p53-containing cancer cells (Fig. 2) . Remarkably, knockdown of 20 SPIN1 inhibited xenograft tumorigenesis derived from human colon cancer cells, which was 21 much more significantly in HCT116 p53+/+ cells than in HCT116 p53-/-cells (Fig. 7) . These results
22
demonstrate that SPIN1 can promote tumor growth and survival by inactivating p53 and its 23 pathway (Fig. 6E ).
24
Intriguingly, we also found that SPIN1 ablation had a moderate inhibitory effect on cell growth 25 in p53-null HCT116 cells in vitro and in vivo as mentioned above ( Fig. 2 and 7) . These findings
26
suggest that SPIN1 might also possess p53-independent oncogenic effects, which might be 27 explained by two possible mechanisms. First, SPIN1 has been reported to execute its oncogenic clue that dysregulation of SPIN1 may perturb ribosome biogenesis. In fact, in our current study,
4
we observed that SPIN1 deletion per se increases the levels of ribosome-free uL18 and uL5, 5 accompanying elevated p53 protein levels, which recapitulates the effects of ribosomal stress.
6
Our observation that p53 induction caused by SPIN1 depletion could be abrogated by 7 knockdown of either uL18 or uL5 further supports this hypothesis. Therefore, while it is 8 conceivable that SPIN1 counteracts p53 by blocking the interaction between uL18 and MDM2 as 9 discussed above, the mechanism by which disruption of SPIN1 causes ribosomal stress may be 10 also responsible for p53 activation.
11
In summary, our findings unveil SPIN1 as another novel and important regulator of the MDM2-12 p53 pathway by predominantly inhibiting the association of uL18 with MDM2 to modulate p53 13 activity ( Fig. 6E ) and provide molecular insights into the fine regulation of this pathway as well 14 as a potential target for the future development of an anti-cancer therapy.
16
Materials and Methods
17
Cell culture and transient transfection. Plasmids and antibodies.
31
The Myc-tagged SPIN1 plasmid was generated by inserting the full-length cDNA amplified by GST fusion protein-protein interaction assay.
23
GST-tagged SPIN1 or GST-tagged uL18 fragments were expressed in E. coli and conjugated
24
with glutathione-Sepharose 4B beads (Sigma-Aldrich). His-tagged SPIN1 and His-tagged uL18 CellQuest (BD Biosciences) and Modfit (Verity, Topsham, ME, USA) software programs.
29
Cell viability assay.
30
To assess the long-term cell survival, the Cell Counting Kit-8 (CCK-8) (Dojindo Molecular Colony formation assay.
8
Cells were trypsinized and seeded at equal number of cells on 60-mm plates. Media were 9 changed every 4 days until the colonies were visible. Puromycin was added into the media for 10 selection at a concentration of 2 µg/ml. Cells were fixed with methanol and stained with crystal 11 violet solution at RT for 30 min. ImageJ was used for quantification of the colonies.
13
Western blot analysis.
14 Cells were harvested and lysed in lysis buffer consisting of 50 mM Tris/HCl (pH 7.5), 0.5% examined under a confocal microscope (Nikon, ECLIPSE Ti2).
22
Sucrose gradient fractionation and ribosome profiling.
23
This assay was performed following the protocol previously described 57 . Briefly, cells were 24 harvested at 70-80% confluence after halting translation by 100 µg/ml cycloheximide incubation 25 for 10 min. Cells were lysed in lysis buffer (10 mM Tris-HCl (pH 7.4), 5 mM MgCl 2 , 100 mM
26
KCl, 1% Triton X-100) and gently sheared with a 26-gauge needle for 4 times. Lysates were 27 subjected to 10-50% sucrose gradient centrifugation and the fractions were collected through 28 BR-188 Density Gradient Fractionation System (Brandel, Gaithersburg, MD, USA).
30
Generating stable cell lines 31 Briefly, scramble shRNA or SPIN1 shRNAs purchased from Sigma were transfected into 1 HCT116 p53+/+ and HCT116 p53-/-cells using TurboFect reagent. The cells were maintained at 37°C 2 in a 5% CO 2 humidified atmosphere for 48 h and were split to two aliquots, one for WB analysis 3 and the other for selection using final concentration of 2 µg/ml puromycin in growth medium.
5
Mouse xenograft experiments.
6
Seven-week-old female NOD/SCID mice were purchased from Jackson Laboratories. Mice were 
Statistical testing
20
All in vitro experiments were performed in biological triplicate and reproduced at least twice.
21
The Student's two-tailed t-test was used to determine mean difference among groups. P<0.05 followed by WB analysis using antibodies as indicated. 
